IL183321A0 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof - Google Patents
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereofInfo
- Publication number
- IL183321A0 IL183321A0 IL183321A IL18332107A IL183321A0 IL 183321 A0 IL183321 A0 IL 183321A0 IL 183321 A IL183321 A IL 183321A IL 18332107 A IL18332107 A IL 18332107A IL 183321 A0 IL183321 A0 IL 183321A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor
- chromanylurea
- compounds
- inhibit vanilloid
- subtype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63063604P | 2004-11-24 | 2004-11-24 | |
| PCT/US2005/042545 WO2006065484A2 (en) | 2004-11-24 | 2005-11-22 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL183321A0 true IL183321A0 (en) | 2008-04-13 |
Family
ID=36588346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL183321A IL183321A0 (en) | 2004-11-24 | 2007-05-20 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7812019B2 (enExample) |
| EP (2) | EP1844038A2 (enExample) |
| JP (2) | JP4932730B2 (enExample) |
| KR (2) | KR101250824B1 (enExample) |
| CN (2) | CN102161653A (enExample) |
| AU (1) | AU2005316972B2 (enExample) |
| BR (1) | BRPI0518581A2 (enExample) |
| CA (1) | CA2588909A1 (enExample) |
| IL (1) | IL183321A0 (enExample) |
| MX (1) | MX2007006205A (enExample) |
| NZ (1) | NZ555318A (enExample) |
| TW (1) | TW200633712A (enExample) |
| WO (1) | WO2006065484A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954138B (zh) * | 2004-03-02 | 2011-02-16 | 罗斯蒙德公司 | 具有改进电能产生的过程设备 |
| US8538560B2 (en) | 2004-04-29 | 2013-09-17 | Rosemount Inc. | Wireless power and communication unit for process field devices |
| US8145180B2 (en) * | 2004-05-21 | 2012-03-27 | Rosemount Inc. | Power generation for process devices |
| KR101250824B1 (ko) * | 2004-11-24 | 2013-04-05 | 아보트 러보러터리즈 | 바닐로이드 수용체 아형 1(vr1) 수용체를 억제하는크로마닐우레아 화합물 및 이의 용도 |
| US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
| AR056320A1 (es) | 2005-04-22 | 2007-10-03 | Wyeth Corp | Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos |
| JP2009513659A (ja) * | 2005-10-28 | 2009-04-02 | アボット・ラボラトリーズ | Trpv1受容体を阻害するインダゾール誘導体 |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| KR20080111144A (ko) * | 2006-04-18 | 2008-12-22 | 아보트 러보러터리즈 | 바닐로이드 수용체 서브타입 1(vr1)의 길항제 및 이의 용도 |
| US7913566B2 (en) | 2006-05-23 | 2011-03-29 | Rosemount Inc. | Industrial process device utilizing magnetic induction |
| WO2008059339A2 (en) * | 2006-11-13 | 2008-05-22 | Glenmark Pharmaceuticals S.A. | Isoquinoline derivatives as vanilloid receptor modulators |
| CN101563318A (zh) * | 2006-12-20 | 2009-10-21 | 艾博特公司 | 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物 |
| WO2008110863A1 (en) * | 2007-03-15 | 2008-09-18 | Glenmark Pharmaceuticals S.A. | Indazole derivatives and their use as vanilloid receptor ligands |
| JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Trpv1のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| WO2009095726A1 (en) * | 2008-01-29 | 2009-08-06 | Glenmark Pharmaceuticals, S.A. | Acrylamide derivatives as vanilloid receptor 1 modulators |
| JP5305704B2 (ja) * | 2008-03-24 | 2013-10-02 | 富士フイルム株式会社 | 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版 |
| US8250924B2 (en) | 2008-04-22 | 2012-08-28 | Rosemount Inc. | Industrial process device utilizing piezoelectric transducer |
| US8929948B2 (en) | 2008-06-17 | 2015-01-06 | Rosemount Inc. | Wireless communication adapter for field devices |
| EP2310918B1 (en) * | 2008-06-17 | 2014-10-08 | Rosemount, Inc. | Rf adapter for field device with variable voltage drop |
| US8694060B2 (en) | 2008-06-17 | 2014-04-08 | Rosemount Inc. | Form factor and electromagnetic interference protection for process device wireless adapters |
| JP5554328B2 (ja) | 2008-06-17 | 2014-07-23 | ローズマウント インコーポレイテッド | 本質安全の低電圧クランプ回路を備えるフィールド装置用rfアダプタ |
| WO2010023512A1 (en) * | 2008-08-28 | 2010-03-04 | Matrix Laboratories Ltd. | Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them |
| EP2352727A1 (en) * | 2008-10-17 | 2011-08-10 | Abbott Laboratories | Trpv1 antagonists |
| JP2012505907A (ja) * | 2008-10-17 | 2012-03-08 | アボット・ラボラトリーズ | Trpv1拮抗薬 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN101654435B (zh) * | 2009-06-09 | 2014-01-29 | 沈阳药科大学 | N-苯甲基喹啉羧酸类化合物、组合物及其制备方法 |
| US20100318007A1 (en) * | 2009-06-10 | 2010-12-16 | O'brien Donald J | Electromechanical tactile stimulation devices and methods |
| US8626087B2 (en) | 2009-06-16 | 2014-01-07 | Rosemount Inc. | Wire harness for field devices used in a hazardous locations |
| US9674976B2 (en) | 2009-06-16 | 2017-06-06 | Rosemount Inc. | Wireless process communication adapter with improved encapsulation |
| JP2013502444A (ja) | 2009-08-24 | 2013-01-24 | アスセピオン ファーマスーティカル、インコーポレイテッド | キナーゼ阻害剤としての5,6−ビシクロヘテロアリール含有尿素化合物 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| CA2794153C (en) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Substituted indoline derivatives as perk inhibitors |
| US10761524B2 (en) | 2010-08-12 | 2020-09-01 | Rosemount Inc. | Wireless adapter with process diagnostics |
| CA2831146C (en) | 2011-03-25 | 2019-06-04 | Abbvie Inc. | Trpv1 antagonists |
| US9310794B2 (en) | 2011-10-27 | 2016-04-12 | Rosemount Inc. | Power supply for industrial process field device |
| WO2013096223A1 (en) | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
| WO2013096226A1 (en) * | 2011-12-19 | 2013-06-27 | Abbvie Inc. | Trpv1 antagonists |
| US8796328B2 (en) | 2012-06-20 | 2014-08-05 | Abbvie Inc. | TRPV1 antagonists |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| US9783527B2 (en) * | 2014-09-16 | 2017-10-10 | Abbvie Inc. | Indazole ureas and method of use |
| CN109574972A (zh) * | 2018-07-13 | 2019-04-05 | 郑州大学 | 一种3-烷基取代-4-色满酮类化合物及其制备方法 |
| WO2022072741A1 (en) * | 2020-09-30 | 2022-04-07 | Katholieke Universiteit Leuven | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| WO2025161263A1 (zh) * | 2024-01-31 | 2025-08-07 | 深圳晶蛋生物医药科技有限公司 | 一种苯并吗啉类化合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8900565A (nl) | 1989-03-08 | 1990-10-01 | Philips Nv | Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode. |
| IL93610A0 (en) * | 1989-03-08 | 1990-12-23 | Merck Sharp & Dohme | Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them |
| US5374643A (en) | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
| EP0922028A1 (en) * | 1996-08-26 | 1999-06-16 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
| DE60036726T2 (de) * | 1999-11-16 | 2008-02-07 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Harnstoff derivate als entzündungshemmende mittel |
| US6984647B2 (en) * | 2002-05-17 | 2006-01-10 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid VR1 receptor |
| JP2006519806A (ja) * | 2003-03-07 | 2006-08-31 | グラクソ グループ リミテッド | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 |
| KR101250824B1 (ko) * | 2004-11-24 | 2013-04-05 | 아보트 러보러터리즈 | 바닐로이드 수용체 아형 1(vr1) 수용체를 억제하는크로마닐우레아 화합물 및 이의 용도 |
| JP2009513659A (ja) * | 2005-10-28 | 2009-04-02 | アボット・ラボラトリーズ | Trpv1受容体を阻害するインダゾール誘導体 |
-
2005
- 2005-11-22 KR KR1020077014371A patent/KR101250824B1/ko not_active Expired - Fee Related
- 2005-11-22 CN CN2011100508496A patent/CN102161653A/zh active Pending
- 2005-11-22 EP EP05825417A patent/EP1844038A2/en not_active Withdrawn
- 2005-11-22 US US11/285,448 patent/US7812019B2/en not_active Expired - Fee Related
- 2005-11-22 MX MX2007006205A patent/MX2007006205A/es active IP Right Grant
- 2005-11-22 NZ NZ555318A patent/NZ555318A/en not_active IP Right Cessation
- 2005-11-22 EP EP12181173A patent/EP2527339A1/en not_active Withdrawn
- 2005-11-22 WO PCT/US2005/042545 patent/WO2006065484A2/en not_active Ceased
- 2005-11-22 KR KR1020127028557A patent/KR20120137420A/ko not_active Withdrawn
- 2005-11-22 CN CNA2005800467732A patent/CN101443327A/zh active Pending
- 2005-11-22 AU AU2005316972A patent/AU2005316972B2/en not_active Ceased
- 2005-11-22 JP JP2007543471A patent/JP4932730B2/ja not_active Expired - Fee Related
- 2005-11-22 CA CA002588909A patent/CA2588909A1/en not_active Abandoned
- 2005-11-22 BR BRPI0518581-5A patent/BRPI0518581A2/pt not_active IP Right Cessation
- 2005-11-24 TW TW094141323A patent/TW200633712A/zh unknown
-
2007
- 2007-05-20 IL IL183321A patent/IL183321A0/en unknown
-
2010
- 2010-09-03 US US12/875,839 patent/US8440691B2/en not_active Expired - Fee Related
-
2012
- 2012-01-11 JP JP2012003232A patent/JP2012111766A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101250824B1 (ko) | 2013-04-05 |
| WO2006065484A2 (en) | 2006-06-22 |
| NZ555318A (en) | 2011-01-28 |
| JP4932730B2 (ja) | 2012-05-16 |
| KR20070086607A (ko) | 2007-08-27 |
| AU2005316972A1 (en) | 2006-06-22 |
| AU2005316972B2 (en) | 2011-11-10 |
| US20110152250A1 (en) | 2011-06-23 |
| EP1844038A2 (en) | 2007-10-17 |
| CN101443327A (zh) | 2009-05-27 |
| EP2527339A1 (en) | 2012-11-28 |
| BRPI0518581A2 (pt) | 2008-11-25 |
| TW200633712A (en) | 2006-10-01 |
| WO2006065484A3 (en) | 2009-02-19 |
| JP2008532925A (ja) | 2008-08-21 |
| JP2012111766A (ja) | 2012-06-14 |
| US20060128689A1 (en) | 2006-06-15 |
| KR20120137420A (ko) | 2012-12-20 |
| US8440691B2 (en) | 2013-05-14 |
| CA2588909A1 (en) | 2006-06-22 |
| MX2007006205A (es) | 2009-02-13 |
| CN102161653A (zh) | 2011-08-24 |
| US7812019B2 (en) | 2010-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183321A0 (en) | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof | |
| ZA200808691B (en) | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof | |
| AP1916A (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
| EP1773871A4 (en) | COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES | |
| ZA200606313B (en) | Triazole compounds and their use as metabotropic glutamate receptor antagonists | |
| IL192426A0 (en) | Prokineticin 2 receptor antagonists | |
| IL192424A0 (en) | Prokineticin 1 receptor antagonists | |
| EP1814550A4 (en) | ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 | |
| ZA200710169B (en) | Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists | |
| DK1463759T3 (da) | Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf | |
| IL179462A0 (en) | Use of the receptor gpr86 | |
| EP2012779A4 (en) | PROCESS FOR PREPARING INDAZOLYL UREES THAT INHIBIT VANILLOID RECEPTORS OF SUBTYPE 1 (VR1) | |
| HK1111688A (en) | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof | |
| EP1723145A4 (en) | SUBSTITUTED 5,12-DIAZENZOANTHRACENANALOGA | |
| ZA200705114B (en) | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | |
| EP1967519A4 (en) | 3,4-DIHYDROBENZOXAZINE COMPOUND AND VANNILLLOID RECEPTOR 1 ACTIVITY INHIBITORS | |
| GB2409587B (en) | 'Kwicap' | |
| IL179981A0 (en) | Asymmetrically substituted biaryldiphosphine ligands 111 | |
| IL179980A0 (en) | Asymmetrically substituted biaryldiphosphine ligands 1 | |
| HK1121956A (en) | Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof | |
| AU2003278113A8 (en) | Stabilising agent mixture | |
| ZA200804716B (en) | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (VR1) activity | |
| HK1093728A (en) | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor | |
| ZA200700361B (en) | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor | |
| GB0420897D0 (en) | Compounds and uses 3 |